Best Lease SA (BVMT:BL)

Revance Therapeutics Balance Sheet

Financials in millions TND. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	63.62	69.85	39.94	75.98	46.51
Long-Term Investments	59.5	51.58	46.81	29.09	20.45
Loans & Lease Receivables	339.18	328.47	318.61	310.02	296.24
Other Receivables	3.57	2.83	2.17	0.86	2.72
Property, Plant & Equipment	1.97	2.28	2.17	2.5	2.62
Other Intangible Assets	0.07	0.1	0.12	0.19	0.14
Other Current Assets	2.35	1.15	1.08	0.99	0.91
Total Assets	470.26	456.25	410.9	419.62	369.58
Accounts Payable	2.8	2.99	3.48	1.06	1.5
Accrued Expenses	2.66	2.85	3.12	1.77	1.24
Short-Term Debt	24.44	20.68	17.75	24.46	23.46
Current Portion of Long-Term Debt	129.19	109.79	116.79	103.45	42.73
Long-Term Debt	83.74	94.78	92.43	125.44	146.45
Long-Term Leases	100	100	57.2	57.45	57.45
Long-Term Unearned Revenue	10.68	8.78	8.69	6.79	6.27
Current Income Taxes Payable	1.89	2.21	4.18	2.85	1.01
Other Current Liabilities	2.16	0.48	2.08	0.18	0.12
Other Long-Term Liabilities	-	0	-	-	-
Total Liabilities	359.05	343.78	307.14	324.69	281.58
Common Stock	30	30	30	30	30
Additional Paid-In Capital	-	-	-	0.2	3.5
Retained Earnings	37.41	39.99	38.38	32.96	26.53
Comprehensive Income & Other	43.8	45.18	38.08	34.48	30.68
Shareholders' Equity	111.21	112.47	103.76	94.93	88.01
Total Liabilities & Equity	470.26	456.25	410.9	419.62	369.58
Total Debt	337.37	325.25	284.17	310.81	270.09
Net Cash (Debt)	-273.75	-255.4	-244.23	-234.83	-223.58
Net Cash Per Share	-9.12	-	-	-	-
Filing Date Shares Outstanding	30	-	-	-	-
Total Common Shares Outstanding	30	-	-	-	-
Working Capital	244.09	262.06	212.98	252.84	274.98
Book Value Per Share	3.71	-	-	-	-
Tangible Book Value	111.14	112.37	103.64	94.74	87.87
Tangible Book Value Per Share	3.70	-	-	-	-

Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.